MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Mycoses Study Group

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint Dive into the research topics of 'MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis'. Together they form a unique fingerprint.

Medicine & Life Sciences